- Home
- SWVL vs IOBT Comparison
SWVL vs IOBT Comparison
Compare SWVL & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWVL | IOBT |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United Arab Emirates | Denmark |
| Employees | 284 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SWVL | IOBT |
|---|---|---|
| Price | $1.37 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 15.6K | ★ 1.4M |
| Earning Date | 04-02-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $0.14 |
| 52 Week High | $4.99 | $2.79 |
Technical Indicators
Market Signals| Indicator | SWVL | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 34.20 |
| Support Level | $1.34 | $0.14 |
| Resistance Level | $3.83 | $0.22 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 22.41 | 32.11 |
Price Performance
Historical ComparisonAbout SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.